Milatuzumab clinical trials
Also written hLL1 and IMMU-115.
- studies test it
- 7
- open now
- 0
- in phase 3
- 0
- first study started
- 2007
How each study uses milatuzumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2007 (3)
| Year | Studies |
|---|---|
| 2007 | 3 |
| 2008 | 1 |
| 2009 | 2 |
| 2013 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 3
Gilead Sciences (4) · Weill Medical College of Cornell University (1) · Beth Christian (1) · Kaplan Medical Center (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses milatuzumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- Phase Ib Study of SC Milatuzumab in SLECompletedPhase 1Gilead SciencesNCT01845740Written as milatuzumab
- Phase I Study of Milatuzumab for Graft Versus Host DiseaseTerminatedPhase 1Gilead SciencesNCT01663766Written as milatuzumab
- Phase I/II Study of Different Doses and Dose Schedules of Milatuzumab (hLL1) in CLLCompletedPhase 1/2Gilead SciencesNCT00603668Written as milatuzumab
- Phase I/II Study of hLL1 in Multiple MyelomaCompletedPhase 1/2Gilead SciencesNCT00421525Written as milatuzumab
- Phase I Trial of Anti-CD74 (hLL1) Antibody Therapy in B Cell MalignanciesCompletedPhase 1Weill Medical College of Cornell UniversityNCT00504972Written as hLL1
- Veltuzumab and Milatuzumab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin LymphomaCompletedPhase 1/2Beth ChristianNCT00989586Written as milatuzumab
- The Humanized Monoclonal Antibody Milatuzumab for Refractory Chronic Lymphocytic Leukemia (CLL)Status unknownPhase 1/2Kaplan Medical CenterNCT00868478Written as Milatuzumab
Codes
What other systems call milatuzumab · ClinicalTrials.gg INT005438
- MeSH (NLM) C540932milatuzumabOne source NLM
- UNII (FDA) 2OP4E0GC6VMILATUZUMABConfirmed FDA, NLM, Wikidata
- Wikidata Q3857819milatuzumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C66983MilatuzumabOne source FDA
- DrugBank DB12943One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C540932 | milatuzumab | One source NLM |
| UNII (FDA) | 2OP4E0GC6V | MILATUZUMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q3857819 | milatuzumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C66983 | Milatuzumab | One source FDA |
| DrugBank | DB12943 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.